Clinical Nurse Specialist in Elkhart, IN Accepting Medicare

4 Clinical Nurse Specialist nurses found. Showing 1 - 4

Lori Nan Gibson, APN Clinical Nurse Specialist - Psych/Mental Health Medicare: Accepting Medicare Assignments Practice Location: 2600 Oakland Ave, Elkhart, IN 46517 Phone: 574-533-1234    Fax: 574-537-2652

Amanda Jo Richie, RN Clinical Nurse Specialist - Long-Term Care Medicare: Not Enrolled in Medicare Practice Location: 1201 E Beardsley Ave, Elkhart, IN 46514 Phone: 574-206-0086    Fax: 574-970-0604

Toni Klatt-ellis, CNS Clinical Nurse Specialist - Oncology Medicare: Not Enrolled in Medicare Practice Location: 600 East Blvd, Elkhart, IN 46514 Phone: 574-523-3112    Fax: 574-523-7885

Sarah Davis, RN Clinical Nurse Specialist - Long-Term Care Medicare: Not Enrolled in Medicare Practice Location: 1201 E Beardsley Ave, Elkhart, IN 46514 Phone: 574-206-0086    Fax: 574-970-0604

News Archive

Study reports on COVID-19 vaccine uptake and antibody prevalence in England during May 2021

A new study reports this finding, along with varying antibody prevalence among different groups and regions and between different age groups. In the current paper, available as a preprint on the medRxiv* server, the results of the sixth round of the REACT-2 study are reported.

FDA's approval time for medical devices increases

According to MassDevice.com, the online business journal of the medical device industry, medical device approval times under the Food & Drug Administration's 510(k) clearance process jumped 30 percent between 2005 and 2008. MassDevice's exclusive investigation of 10 years of FDA data, Eye on the FDA: H1 2009, shows that approval times for medical devices increased nearly 2 percent — while the number of 510(k) applications declined more than 19 percent — even as the FDA's budgets and staff levels rose.

athenahealth second-quarter total revenue increases 28% to $58.6M

athenahealth, Inc., a leading provider of web-based practice management, electronic health record (EHR), and patient communication services to medical groups, today announced financial and operational results for the second quarter of fiscal year 2010. The Company will conduct a conference call on Friday, July 23, 2010, at 8:00 a.m. Eastern Time to discuss these results and management's outlook for future financial and operational performance.

Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma

Celgene International Sàrl announced that data evaluating combination therapy REVLIMID (lenalidomide) and dexamethasone in patients with high-risk smoldering multiple myeloma were presented during the American Society of Hematology's annual meeting in New Orleans, LA. The landmark study demonstrated REVLIMID and dexamethasone prolonged time to progression, including complete responses, with manageable toxicity.

Read more Medical News

› Verified 6 days ago